Medicx­i's mega-start­up Centes­sa rolls out first da­ta for he­mo­phil­ia drug with plans to charge ahead in­to piv­otal test

When Medicxi ear­li­er this year cob­bled to­geth­er Centes­sa — its Russ­ian nest­ing doll of a biotech start­up with 10 port­fo­lio com­pa­nies fold­ed in­to one — the fo­cus …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER